Results 1 to 10 of about 5,312,533 (302)
Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after ...
Oner Sanli +6 more
semanticscholar +6 more sources
Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial tumours, which tend to recur but are generally not life threatening, and 30% presenting as muscle-invasive disease associated with a high risk of death from distant metastases.
James E, Montie +20 more
+9 more sources
SummaryBladder cancer is the fourth most common cancer in England and Wales. The most common presenting symptom is macroscopic haematuria. The management options for superficial and invasive bladder cancer depend on the stage at presentation. Most superficial bladder cancers are managed by transurethral resection and cytoscopic follow-up. The prognosis
H Y, Leung, T R, Griffiths, D E, Neal
openaire +4 more sources
IntroductionNon-muscle-invasive bladder cancer (NMIBC) is a common and heterogeneous disease; many patients develop recurrent or progress to muscle-invasive disease.
Kelly Ward +4 more
doaj +1 more source
Background: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that ...
Naheema S. Gordon +9 more
doaj +1 more source
Background Bladder cancer (BCa) is the fourth most common malignant tumor with a poor prognosis worldwide. Further exploration and research are needed to unmask the underlying roles and molecular mechanisms of circular RNAs.
Boda Xie +9 more
semanticscholar +1 more source
Background Three-quarters of bladder cancer patients present with early-stage disease (non-muscle-invasive bladder cancer, NMIBC, UICC TNM stages Ta, T1 and Tis); however, most next-generation sequencing studies to date have concentrated on later-stage ...
Anshita Goel +16 more
doaj +1 more source
PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium
The use of immune checkpoint blockade, in particular PD-1 and PD-L1 inhibitors, is now commonplace in many clinical settings including the treatment of muscle-invasive bladder cancer (MIBC).
Alexander C. Dowell +9 more
doaj +1 more source
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary ...
T. Flaig +37 more
semanticscholar +1 more source
Hub gene associated with prognosis in bladder cancer is a novel therapeutic target [PDF]
Objective Bladder cancer is a clinical and social conundrum due to its high incidence and recurrence rate. It is urgent to find new targets for the diagnosis and treatment of bladder cancer and improve the prognosis and survival rate of bladder cancer ...
Dengpan Fang +4 more
doaj +2 more sources

